Context Therapeutics (CNTX) said Tuesday it dosed the first patient in the phase 1 study of CTIM-76, its lead drug candidate targeting Claudin 6-positive gynecologic and testicular cancers.
Initial data from the trial is expected to be released in H1 2026, the company said.
The phase 1 trial seeks to evaluate the safety and efficacy of CTIM-76 in patients with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancer.
Up to 70 patients will be enrolled in the phase 1 trial to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity, including response rate, duration, and disease control, the company said.
Shares of Context Therapeutics were up 1% in after-hours activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。